Jazz Pharmaceuticals (NAS: JAZZ) is expected to report Q3 earnings on Nov. 8. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals's revenues will grow 143.6% and EPS will grow 57.8%.
The average estimate for revenue is $178.6 million. On the bottom line, the average EPS estimate is $1.31.
Last quarter, Jazz Pharmaceuticals notched revenue of $129.5 million. GAAP reported sales were much higher than the prior-year quarter's $64.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.09. GAAP EPS of $0.45 for Q2 were 37% lower than the prior-year quarter's $0.71 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 90.3%, 450 basis points worse than the prior-year quarter. Operating margin was 37.7%, 1,470 basis points worse than the prior-year quarter. Net margin was 21.0%, 3,040 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $611.8 million. The average EPS estimate is $4.77.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 210 members out of 276 rating the stock outperform, and 66 members rating it underperform. Among 69 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 48 give Jazz Pharmaceuticals a green thumbs-up, and 21 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals is buy, with an average price target of $65.63.
Add Jazz Pharmaceuticals to My Watchlist.
The article Can Jazz Pharmaceuticals Meet These Numbers? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.